Sessions/Tracks

Precision oncology is revolutionizing cancer care by tailoring treatments to the genetic and molecular characteristics of tumors. This track highlights the role of tumor genomic profiling in identifying actionable mutations, predicting therapy response, and guiding clinical decisions. Advances in multi-omics integration are uncovering new layers of tumor complexity, opening doors for targeted approaches. Discussions will also cover ethical considerations and challenges in implementing genomic testing in diverse populations. By aligning diagnostics with therapies, precision oncology ensures individualized cancer treatment.

• Multi-omics integration in oncology
• Genomic biomarkers and therapeutic targets
• Ethical and clinical adoption challenges

Understanding the mutational landscapes of cancer is central to unraveling disease progression and therapeutic resistance. This track delves into genomic alterations, molecular signatures, and predictive biomarkers that drive cancer heterogeneity. Participants will explore advances in next-generation sequencing, biomarker-driven drug discovery, and cross-tumor mutation patterns. The discussion also emphasizes translating genomic knowledge into clinical applications that benefit patients across cancer types. By decoding cancer genomes, researchers can pave the way for better diagnostics and novel treatments.

• Next-generation sequencing for mutation discovery
• Predictive and prognostic biomarkers
• Cross-tumor mutation signatures

Targeted therapies are rapidly evolving to address cancer mutations and resistance pathways. This track focuses on the next generation of targeted drugs, including small molecules, bispecific antibodies, and fusion inhibitors. Insights will be shared on design strategies that improve selectivity while minimizing toxicity. Attention will also be given to combination regimens that enhance response rates. With breakthroughs in tumor biology, novel therapeutic agents are moving closer to clinical reality, offering renewed hope for patients with resistant cancers.

• Small molecules targeting novel pathways
• Bispecific and multispecific antibodies
• Overcoming acquired resistance with new agents

Radiotherapy and surgical oncology continue to advance with innovations that improve precision and reduce invasiveness. This track highlights developments such as proton therapy, image-guided radiotherapy, and organ-preserving surgical techniques. Robotic-assisted procedures and intraoperative imaging are transforming the surgical landscape, allowing for higher accuracy and faster recovery. Experts will also discuss integrating radiation with immunotherapy and systemic agents for synergistic effects. These innovations are reshaping the role of surgery and radiation in comprehensive cancer care.

• Proton and particle-based radiotherapy
• Robotics and image-guided surgical oncology
• Combination radiotherapy with systemic agents

Early detection is the key to improving cancer survival rates. This track explores how liquid biopsies and advanced imaging are redefining cancer diagnostics. Topics include circulating tumor DNA, exosomes, and AI-driven imaging platforms that enable non-invasive and real-time monitoring. Early diagnosis also reduces treatment intensity and improves quality of life for patients. Case studies will showcase applications across multiple cancer types. The integration of diagnostics with digital technologies promises a future of proactive oncology.

• Circulating biomarkers and liquid biopsy platforms
• AI-driven imaging technologies
• Integrating early detection into routine practice

The tumor microenvironment (TME) plays a critical role in cancer growth, immune evasion, and metastasis. This track examines the interplay between cancer cells, stromal cells, and immune infiltrates within the TME. Advances in imaging, single-cell sequencing, and 3D models are providing deeper insights into metastatic pathways. Understanding these interactions offers opportunities for novel therapeutic strategies that target not only the tumor but also its supportive ecosystem. Attendees will explore how disrupting the TME can halt progression and metastasis.

• Single-cell mapping of tumor microenvironment
• Mechanisms of metastasis and invasion
• Targeting stromal-immune interactions

Therapy resistance remains one of the greatest hurdles in oncology. This track focuses on mechanisms of resistance to chemotherapy, targeted therapies, and immunotherapies. Cutting-edge research into adaptive resistance pathways, epigenetic changes, and tumor evolution will be explored. Strategies such as adaptive trial designs, novel drug combinations, and synthetic lethality approaches offer promising solutions. Discussions will also highlight how computational modeling can predict resistance. Ultimately, this track provides insights into overcoming therapeutic roadblocks and extending patient survival.

• Mechanisms of resistance across treatment modalities
• Adaptive strategies to overcome resistance
• Computational prediction of resistance patterns

While CAR-T therapy has shown remarkable success in hematologic cancers, translating this progress into solid tumors presents new challenges and opportunities. This track examines advances in CAR-T design, TCR-engineered cells, and strategies to enhance persistence and tumor penetration. Experts will discuss safety management, off-target effects, and innovations such as armored CARs. Collaborative research is accelerating the clinical translation of these therapies into solid tumor settings. The sessions aim to highlight how engineered immune cells are reshaping the landscape of oncology therapeutics.

• Next-generation CAR-T engineering for solid tumors
• Overcoming barriers to tumor penetration
• TCR and NK-cell based immunotherapies

Traditional trial models often fall short in capturing the complexity of cancer biology. This track explores adaptive and personalized clinical trial designs that accelerate therapeutic development. Topics include basket and umbrella trials, real-time biomarker integration, and patient-centric endpoints. Experts will also discuss the role of digital platforms and AI in adaptive trial monitoring. By refining methodologies, these innovative designs aim to shorten timelines and deliver effective treatments to patients faster.

• Basket and umbrella trial frameworks
• Biomarker-driven trial stratification
• AI and digital tools in adaptive trials

Artificial intelligence is rapidly transforming cancer diagnosis and management. This track focuses on computational oncology tools for predictive modeling, early detection, and treatment optimization. Machine learning algorithms are enabling more accurate imaging interpretation, drug discovery, and personalized therapy selection. Ethical considerations, data bias, and regulatory frameworks will also be discussed. By merging computational insights with clinical practice, AI is set to improve outcomes and accelerate innovation in oncology.

• AI-powered imaging and pathology
• Predictive modeling for therapy selection
• Ethics and regulation of AI in oncology

The surgical oncology landscape is shifting toward precision and minimally invasive approaches. This track highlights robotic-assisted surgeries, laparoscopic innovations, and image-guided intraoperative procedures. Benefits such as reduced recovery times, improved accuracy, and organ preservation are driving adoption worldwide. Integration of robotics with AI and augmented reality is pushing surgical precision to new heights. Attendees will explore future directions where technology and surgical expertise merge seamlessly to redefine cancer care.

• Robotic-assisted surgery in complex cancers
• Laparoscopic and image-guided innovations
• AR/VR applications in surgical oncology

Nanotechnology offers novel solutions for overcoming barriers in drug delivery and tumor targeting. This track explores nanoparticle-based delivery systems, smart drug carriers, and multifunctional nanoplatforms for imaging and therapy. Innovations in nanomedicine are enabling enhanced drug stability, precision targeting, and reduced toxicity. Clinical translation of nanotherapies is gaining momentum, particularly in resistant and recurrent cancers. By bridging engineering with medicine, nanotechnology is driving the next wave of oncology breakthroughs.

• Nanoparticle-based targeted delivery systems
• Theranostic nanoplatforms for imaging and therapy
• Clinical translation and safety of nanomedicine

Oncology care extends beyond treatment to include survivorship and quality of life. This track emphasizes palliative care, long-term side-effect management, and psychosocial support for cancer patients. Advances in symptom control, integrative therapies, and survivorship care plans will be highlighted. Attendees will also discuss caregiver support and models for holistic cancer care. The track reinforces the importance of patient-centered approaches that prioritize dignity, comfort, and long-term well-being.

• Innovations in palliative and supportive care
• Survivorship care planning and rehabilitation
• Psychosocial support and caregiver well-being

Preventive and therapeutic vaccines represent a promising frontier in oncology. This track examines advances in neoantigen-based vaccines, viral vector platforms, and combination immunotherapies. Discussions will also address the integration of vaccines with checkpoint inhibitors and other modalities. Preventive immunology strategies against virus-associated cancers are gaining traction globally. By leveraging the immune system’s memory, cancer vaccines hold potential for both prevention and durable remission.

• Neoantigen and personalized vaccine platforms
• Combination immunotherapies with vaccines
• Preventive vaccines for virus-driven cancers

Pediatric and rare cancers present unique biological and clinical challenges that demand specialized approaches. This track covers breakthroughs in molecular characterization, targeted therapies, and precision medicine for rare malignancies. Collaborative networks and data-sharing initiatives are accelerating research progress in underrepresented cancers. Sessions will also highlight patient advocacy and regulatory pathways for rare cancer drug approvals. By focusing on these areas, the track ensures that innovation benefits all patient groups, including those often overlooked.

• Molecular profiling of pediatric and rare cancers
• Novel therapies and compassionate use access
• Advocacy and regulatory perspectives in rare cancers

Understanding cancer risk factors and prevention strategies is vital to reducing global incidence. This track explores advances in epidemiology, lifestyle interventions, and population-based screening programs. Experts will discuss genetic predispositions, environmental exposures, and emerging risk models. Innovations in screening, including AI-assisted imaging and non-invasive tests, will be emphasized. The goal is to create sustainable, equitable prevention programs that lower cancer burdens worldwide.

• Population-based cancer screening programs
• Genetic and environmental risk models
• Lifestyle and preventive oncology strategies

Global disparities in cancer care remain a pressing challenge. This track focuses on health equity, access to therapies, and improving care delivery in low-resource settings. Discussions will address strategies for affordable diagnostics, policy interventions, and capacity building. Real-world examples will showcase successful models of equitable oncology care. By highlighting global collaboration, this track aims to ensure that innovation benefits patients regardless of geography or socio-economic status.

• Policy and global health frameworks for equity
• Affordable diagnostics and therapy models
• Capacity building in low- and middle-income countries

Translational oncology bridges laboratory discoveries with clinical practice. This track highlights the latest progress in taking molecular and cellular insights into therapeutic development. Sessions will cover novel biomarkers, drug discovery pipelines, and early-phase clinical trials. Emphasis will be placed on collaborative research models and multi-institutional studies. Attendees will learn how translational science accelerates the journey from innovation to patient benefit.

• Novel biomarker-driven therapeutic development
• Preclinical models for translational oncology
• Early-phase trial design and implementation

Integrative oncology is redefining supportive cancer care by combining conventional medicine with evidence-based complementary approaches. This track explores nutrition, physical activity, mind–body interventions, and digital health tools in oncology care. Research on reducing treatment side effects and enhancing resilience will also be featured. Innovations in supportive care are helping patients navigate therapy more effectively while improving overall outcomes. By adopting a holistic approach, integrative oncology prioritizes both survival and quality of life.

• Nutrition and lifestyle interventions in oncology
• Mind–body and digital health strategies
• Reducing toxicity and enhancing resilience